Canada Markets close in 1 hr 53 mins

Aphria, Aurora Among Top Performers As Canadian Cannabis Sales Spike

Priya Nigam
·2 mins read

Canada’s recreation cannabis sales grew by 19% in March to reach CA$181.1 million ($131.5 million), ahead of most U.S. states, according to Cantor Fitzgerald.

Analyst Pablo Zuanic said that Canada’s March sales data was significantly ahead of Cantor’s mid-single digit estimate, partly due to pantry loading, but also on account of continued Cannabis 2.0 rollouts.

Ratings And Price Targets

Cantor analyst Pablo Zuanic maintained the following ratings and price targets on cannabis stocks:

Overweight

  • Aurora Cannabis Inc. (NYSE: ACB) with a CA$27 price target. 

  • Aphria Inc. (NYSE: APHA) with a CA$9.55 price target. 

  • OrganiGram Holdings Inc (NASDAQ: OGI) with a price target of CA$5.60. 

Neutral

  • Canopy Growth Corp (NYSE: CGC) with a price target of CA$25. 

  • Tilray Inc (NASDAQ: TLRY) with a price target of $8. 

Underweight

  • Hexo Corp (NYSE: HEXO) with a price target of CA$0.72.

Cantor's Cannabis Takeaways 

Comparing Canada’s 17th month of recreational cannabis sales with Colorado's figures indicates that the country’s market may grow to CA$14 billion by the end of 2024, Zuanic said in the industry note.

So far, the best performers in the first quarter are Aphria, with 53% sales growth, and Aurora Cannabis and Tilray, with sales growth in the mid-20% range, the analyst said.

Canopy Growth is scheduled to report its March quarter results Friday.

Zuanic named Aphria and Aurora Cannabis as top picks.

Related Links: 

Canopy Growth Set To Become Cannabis Sector Leader, Says BofA

The Week In Cannabis: A Great Week For Stocks Driven By Confusion, Aurora's Rally, New Advisors To Benzinga

Courtesy photo

  • Analista: Aphria y Aurora Cannabis Posicionados para Liderar Ventas en Canadá

Latest Ratings for APHA

Date

Firm

Action

From

To

May 2020

Cantor Fitzgerald

Maintains

Overweight

May 2020

Cantor Fitzgerald

Maintains

Overweight

Apr 2020

CIBC

Maintains

Neutral

View More Analyst Ratings for APHA
View the Latest Analyst Ratings

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.